The world's first drug eluting Bioresorbable Vascular Scaffold (BVS) which was launched on December 19, in India and is a first of its kind device for the treatment of coronary artery disease (CAD) that works by restoring blood flow to the heart similar to a metallic stent but then dissolves into the body over time, leaving behind a treated vessel that may resume more natural function and movement, has caught the attention of well known hospitals in Mumbai.
Cardiologists from Bombay Hospital, Jaslok Hospital and Asian Heart Institute successfully used BVS on their patients on December 20, just a day after its launch.
Dr. B.K. Goyal, Director, Cardiology, Bombay Hospital, along with his team of doctors, first performed this breakthrough procedure in a 37-year-old man and Dr. A.B. Mehta, Dr. Ajit Desai and Dr. S.R. Handa with a team of doctors at Jaslok Hospital placed the Bioresorbable stent, ‘AbsorbTM’ in a 57-year-old man, for the first time after its official launch on Thursday morning.
According to Dr. Goyal, young patients will benefit from this therapy as it provides options for future interventions unobstructed by a permanent implant.
“It will eliminate sources of vessel inflammation and irritation and restore it to a more natural state. Also, patients may no longer require the prolonged anti-platelet (DAPT) therapy for lifelong,” said Dr. Goyal.
While Dr. Mehta explained, “The learning curve for the doctors is simple and easy for these kinds of stents. One must possess full knowledge about the stent and the blocked area in the artery should be adequately opened before placing such a stent. In times to come, this will replace currently used metallic stents completely.”
Dr. Nilesh Gautam and Dr. Paveen Kulkarni from Asian Heart Institute performed the procedure on 49-year-old Sushma Mallawat who was a high risk case with diabetes, acute coronary syndrome and symptoms of breathlessness, chest pain. Her heart pumping was less than 35 per cent and she had a 100 per cent blockage in her left anterior descending artery (LADA).
According to the doctors, this new generation bioresorbable stent serve the same purpose as that of the normal stent but is manufactured from a material that dissolves in the body over time.
“Thrombolysis in myocardial infarction has been achieved which is considered as the best,” said doctors.